369 related articles for article (PubMed ID: 28507103)
21. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.
Tan B; Young DA; Lu ZH; Wang T; Meier TI; Shepard RL; Roth K; Zhai Y; Huss K; Kuo MS; Gillig J; Parthasarathy S; Burkholder TP; Smith MC; Geeganage S; Zhao G
J Biol Chem; 2013 Feb; 288(5):3500-11. PubMed ID: 23239881
[TBL] [Abstract][Full Text] [Related]
22. Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
Sociali G; Raffaghello L; Magnone M; Zamporlini F; Emionite L; Sturla L; Bianchi G; Vigliarolo T; Nahimana A; Nencioni A; Raffaelli N; Bruzzone S
Oncotarget; 2016 Jan; 7(3):2968-84. PubMed ID: 26658104
[TBL] [Abstract][Full Text] [Related]
23. Novel NAPRT specific antibody identifies small cell lung cancer and neuronal cancers as promising clinical indications for a NAMPT inhibitor/niacin co-administration strategy.
Cole J; Guiot MC; Gravel M; Bernier C; Shore GC; Roulston A
Oncotarget; 2017 Sep; 8(44):77846-77859. PubMed ID: 29100430
[TBL] [Abstract][Full Text] [Related]
24. Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Zheng X; Bair KW; Bauer P; Baumeister T; Bowman KK; Buckmelter AJ; Caligiuri M; Clodfelter KH; Feng Y; Han B; Ho YC; Kley N; Li H; Liang X; Liederer BM; Lin J; Ly J; O'Brien T; Oeh J; Oh A; Reynolds DJ; Sampath D; Sharma G; Skelton N; Smith CC; Tremayne J; Wang L; Wang W; Wang Z; Wu H; Wu J; Xiao Y; Yang G; Yuen PW; Zak M; Dragovich PS
Bioorg Med Chem Lett; 2013 Oct; 23(20):5488-97. PubMed ID: 24021463
[TBL] [Abstract][Full Text] [Related]
25. Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery.
Ghanem MS; Caffa I; Del Rio A; Franco J; Parenti MD; Monacelli F; Cea M; Khalifa A; Nahimana A; Duchosal MA; Ravera S; Bertola N; Bruzzone S; Nencioni A; Piacente F
Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890147
[TBL] [Abstract][Full Text] [Related]
26. Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer.
Kudo K; Nomura M; Sakamoto Y; Ito S; Morita M; Kawai M; Yamashita Y; Ito K; Yamada H; Shima H; Yaegashi N; Tanuma N
FEBS Lett; 2020 May; 594(9):1379-1388. PubMed ID: 31950503
[TBL] [Abstract][Full Text] [Related]
27. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma.
Heske CM; Davis MI; Baumgart JT; Wilson K; Gormally MV; Chen L; Zhang X; Ceribelli M; Duveau DY; Guha R; Ferrer M; Arnaldez FI; Ji J; Tran HL; Zhang Y; Mendoza A; Helman LJ; Thomas CJ
Clin Cancer Res; 2017 Dec; 23(23):7301-7311. PubMed ID: 28899971
[No Abstract] [Full Text] [Related]
28. Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
Zheng X; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Oh A; Wang W; Zak M; Wang Y; Yuen PW; Bair KW
Bioorg Med Chem Lett; 2014 Jan; 24(1):337-43. PubMed ID: 24279990
[TBL] [Abstract][Full Text] [Related]
29. Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer.
Santidrian AF; LeBoeuf SE; Wold ED; Ritland M; Forsyth JS; Felding BH
DNA Repair (Amst); 2014 Nov; 23():79-87. PubMed ID: 25263164
[TBL] [Abstract][Full Text] [Related]
30. Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity.
Soncini D; Caffa I; Zoppoli G; Cea M; Cagnetta A; Passalacqua M; Mastracci L; Boero S; Montecucco F; Sociali G; Lasigliè D; Damonte P; Grozio A; Mannino E; Poggi A; D'Agostino VG; Monacelli F; Provenzani A; Odetti P; Ballestrero A; Bruzzone S; Nencioni A
J Biol Chem; 2014 Dec; 289(49):34189-204. PubMed ID: 25331943
[TBL] [Abstract][Full Text] [Related]
31. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD
Guo J; Lam LT; Longenecker KL; Bui MH; Idler KB; Glaser KB; Wilsbacher JL; Tse C; Pappano WN; Huang TH
Biochem Biophys Res Commun; 2017 Sep; 491(3):681-686. PubMed ID: 28756225
[TBL] [Abstract][Full Text] [Related]
32. Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors.
Shames DS; Elkins K; Walter K; Holcomb T; Du P; Mohl D; Xiao Y; Pham T; Haverty PM; Liederer B; Liang X; Yauch RL; O'Brien T; Bourgon R; Koeppen H; Belmont LD
Clin Cancer Res; 2013 Dec; 19(24):6912-23. PubMed ID: 24097869
[TBL] [Abstract][Full Text] [Related]
33. Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.
Chini CC; Guerrico AM; Nin V; Camacho-Pereira J; Escande C; Barbosa MT; Chini EN
Clin Cancer Res; 2014 Jan; 20(1):120-30. PubMed ID: 24025713
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
Sharma P; Xu J; Williams K; Easley M; Elder JB; Lonser R; Lang FF; Lapalombella R; Sampath D; Puduvalli VK
Neuro Oncol; 2022 Feb; 24(2):229-244. PubMed ID: 34260721
[TBL] [Abstract][Full Text] [Related]
35. Inhibitors of NAD
Ghanem MS; Caffa I; Monacelli F; Nencioni A
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396769
[TBL] [Abstract][Full Text] [Related]
36. NAD
Moore AM; Zhou L; Cui J; Li L; Wu N; Yu A; Poddar S; Liang K; Abt ER; Kim S; Ghukasyan R; Khachatourian N; Pagano K; Elliott I; Dann AM; Riahi R; Le T; Dawson DW; Radu CG; Donahue TR
Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33597293
[TBL] [Abstract][Full Text] [Related]
37. NAMPT and NAPRT, Key Enzymes in NAD Salvage Synthesis Pathway, Are of Negative Prognostic Value in Colorectal Cancer.
Li XQ; Lei J; Mao LH; Wang QL; Xu F; Ran T; Zhou ZH; He S
Front Oncol; 2019; 9():736. PubMed ID: 31448236
[TBL] [Abstract][Full Text] [Related]
38. The sodium phosphate cotransporter family and nicotinamide phosphoribosyltransferase contribute to the daily oscillation of plasma inorganic phosphate concentration.
Miyagawa A; Tatsumi S; Takahama W; Fujii O; Nagamoto K; Kinoshita E; Nomura K; Ikuta K; Fujii T; Hanazaki A; Kaneko I; Segawa H; Miyamoto KI
Kidney Int; 2018 May; 93(5):1073-1085. PubMed ID: 29398136
[TBL] [Abstract][Full Text] [Related]
39. Properly Substituted Benzimidazoles as a New Promising Class of Nicotinate Phosphoribosyltransferase (NAPRT) Modulators.
Baldassarri C; Giorgioni G; Piergentili A; Quaglia W; Fontana S; Mammoli V; Minazzato G; Marangoni E; Gasparrini M; Sorci L; Raffaelli N; Cappellacci L; Petrelli R; Del Bello F
Pharmaceuticals (Basel); 2023 Jan; 16(2):. PubMed ID: 37259338
[TBL] [Abstract][Full Text] [Related]
40. NAPRT, but Not NAMPT, Provides Additional Support for NAD Synthesis in Esophageal Precancerous Lesions.
Wang N; Pan D; Wang X; Su M; Wang X; Yan Q; Sun G; Wang S
Nutrients; 2022 Nov; 14(22):. PubMed ID: 36432602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]